Labcorp (LH) announced it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. FDA to aid in the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting. Developed by Roche Diagnostics (RHHBY), Labcorp plans to make the test available nationwide by early 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH: